Targeted therapy for breast cancer: An overview of drug classes and outcomes | | 2022 |
Trastuzumab biosimilar HLX02 versus reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a model-based economic evaluation for China | | |
Radiotheranostics in oncology: current challenges and emerging opportunities | Nature Reviews Clinical Oncology | |
Cardioprotection for Anti-HER2 Therapy: Considerations for Primary Prevention and Use in Mildly Reduced Left Ventricular Ejection Fraction. | Current Oncology Reports | 2022 |
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings. | Npj Breast Cancer | 2022 |
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study. | BioDrugs | 2022 |
Cancer Immunotherapies: What the Perioperative Physician Needs to Know. | Current Oncology Reports | 2022 |
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies. | Investigational New Drugs | 2022 |
The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients. | Molecular Diagnosis and Therapy | 2022 |
Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer. | Advances in Therapy | 2022 |
Novel Therapies to Overcome HER2 Therapy Resistance in Breast Cancer | Resistance To Targeted Anti-cancer Therapeutics | 2019 |
Heart failure prevention and monitoring strategies in HER2-positive breast cancer: a narrative review | Breast Cancer Research and Treatment | 2021 |
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now | Npj Breast Cancer | 2021 |
Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial | BioDrugs | 2021 |
The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancer | Expert Review of Pharmacoeconomics and Outcomes Research | 2021 |
Trastuzumab administration during pregnancy: an update | BMC Cancer | 2021 |
Immunogenicity Risk Profile of Nanobodies | Frontiers in Immunology | 2021 |
Facile protein conjugation of platinum for light-activated cytotoxic payload release | Chemical Communications | 2021 |
A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects | Cancer Chemotherapy and Pharmacology | 2021 |
Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis | Breast Cancer Research and Treatment | 2020 |
Risks at the Intersection of Research and Oncology Nursing | Seminars in Oncology Nursing | 2020 |
Commentary on ICH guideline on genomic sampling and data management-enabling opportunities in drug development and patient treatment | British Journal of Clinical Pharmacology | 2020 |
Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer | Cardio-Oncology | 2020 |
Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials | Cancer Chemotherapy and Pharmacology | 2020 |
Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars | Analytical and Bioanalytical Chemistry | 2020 |
Current Considerations on Characterization of Immune Response to Multi-Domain Biotherapeutics | BioDrugs | 2020 |
Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study | Journal of Clinical Pharmacology | 2019 |
Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer | Oncologist | 2019 |
Clinical development of CT-P6 in HER2 positive breast cancer | Expert Opinion on Biological Therapy | 2019 |
Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial | Cancer Communications | 2019 |
Contemporary Role of Echocardiography for Clinical Decision Making in Patients During and After Cancer Therapy | JACC: Cardiovascular Imaging | 2018 |
In-Use Physicochemical and Biological Stability of the Trastuzumab Biosimilar CT-P6 Upon Preparation for Intravenous Infusion | BioDrugs | 2018 |
Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit | European Journal of Obstetrics, Gynecology and Reproductive Biology | 2018 |
Human epidermal growth factor receptor 2 status of gastric cancer patients in Asia: results from a large, multicountry study | Asia-Pacific Journal of Clinical Oncology | 2017 |
A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects | Cancer Chemotherapy and Pharmacology | 2017 |
Cardio-oncology Related to Heart Failure: Epidermal Growth Factor Receptor Target-Based Therapy | Heart Failure Clinics | 2017 |
Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch | Clinical and Translational Science | 2017 |
Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer | Internal and Emergency Medicine | 2016 |
Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics | Clinical Pharmacokinetics | 2016 |
Trastuzumab in the Treatment of Breast Cancer | BioDrugs | 2016 |
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology | American Journal of Clinical Pathology | 2016 |
Cardiovascular prevention in the cancer survivor | Current Atherosclerosis Reports | 2015 |
Multipopulation Tailoring Clinical Trials: Design, Analysis, and Inference Considerations | Therapeutic Innovation and Regulatory Science | 2014 |
Cardiac toxicity in cancer survivors | Cancer | 2013 |
Role of Pharmacogenetics in Registration Processes | | 2012 |
Pharmacokinetic mAb-mAb interaction: anti-VEGF mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenografts | AAPS Journal | 2012 |
Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? | Oncologist | 2012 |
HER2 amplification in gastroesophageal adenocarcinoma: correlation of two antibodies using gastric cancer scoring criteria, H score, and digital image analysis with fluorescence in situ hybridization | American Journal of Clinical Pathology | 2012 |
Issues facing therapeutic monoclonal antibodies for the future | | 2012 |
Trastuzumab in HER2-positive metastatic gastric cancer: profile report | BioDrugs | 2011 |